Frankfurt am Main, March 25, 2015 -- Moody's Investors Service, ("Moody's") has today assigned a Ba1 Corporate Family rating and a Ba1-PD Probability of Default rating to Hikma Pharmaceutical Plc, the parent company of the Hikma group. Concurrently Moody's has assigned a Ba1 rating to the proposed benchmark-sized senior unsecured guaranteed notes to be issued by Hikma Pharmaceuticals Plc. The outlook on all ratings is stable.

Vollständigen Artikel bei Moodys lesen